Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Timolol for Mohs Scalp Wounds
NCT07583862Phase 2Not yet recruiting
- Sponsor
- Geisinger
- Start
- Dec 2026
- Primary completion
- Jul 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of timolol maleate gel + placebo in surgical wound (2 arms), sponsored by Geisinger. Primary endpoints: Healing At 12 Weeks and Scar Cosmesis at 12 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
timolol maleate gel + placebo
03
Conditions
surgical wound
Beyond the preview
Go deeper on NCT07583862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07583862.